Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 25

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 4
Chunk 25
---
Item 4. Controls and Procedures.

Evaluation of Disclosure
Controls and Procedures

As of the end of the period
covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is
the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design and operation of the
Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable
level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and
Principal Financial Officer have concluded that the Company’s disclosure controls and procedures were ineffective at this reasonable
assurance level as of the period covered.

Changes in Internal Controls
over Financial Reporting

In connection with the evaluation
of the Company’s internal controls during the period commencing on April 1, 2024 and ending on December 31, 2024, David Koos, who
serves as the Company’s Principal Executive Officer, Principal Financial Officer has determined that there were no changes to the
Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect,
the Company’s internal controls over financial reporting.

  24  

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.